Prevent Unwanted Immunogenicity in Biotherapeutics
Protein therapeutics of all types can potentially elicit immune responses when administered to humans. The consequences of such anti-drug antibodies (ADAs) may include partial or complete loss of drug efficacy, altered pharmacokinetics, or cross reactions with patient’s endogenous proteins. In certain situations, these effects can even result in life-threatening reactions.
Lonza’s immunogenicity assessment services address the challenge of unwanted immune responses throughout the drug development cycle. By managing potential drug immunogenicity at the earliest possible stage, you can save time and money while creating a safer biotherapeutic protein or antibody for the market.
Our Epibase™ In Silico immunoprofiling services and In Vitro cellular assays predict and compare the immunogenicity risk potential of biotherapeutic protein and antibody targets based on their T cell epitope content. Lonza’s Applied Protein Services experts will work with you to customize your package based on your protein target list and timeline. Our goal is to provide you with the best chance of success when you enter the clinic.